Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

FB Nasdaq FB Facebook

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of the stock remained 1.07million shares. The beta of the stock remained 2.40. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) insider ownership is 1.80%.

Sangamo Biosciences Inc (NASDAQ:SGMO) was the target of a significant increase in short interest during the month of January. As of March 14th, there was short interest totalling 11,166,388 shares, an increase of 24.8% from the February 28th total of 8,950,725 shares, Stock Ratings Network.com reports. Sangamo Biosciences, Inc. (NASDAQ:SGMO) dropped -5.21 percent to $16.75 Thursday on volume of 1.71million shares. The intra-day range of the stock was $15.91 to $17.64. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has a market capitalization of $1.12billion.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that Lexicon management will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 9:20 AM EDT in New York City. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) management will provide an overview of Lexicon’s clinical development programs and milestones. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock on Apr 03, 2014 reported a decrease of -6.68% to the closing price of $1.69. Its fifty two weeks range is $1.62 -$3.18. The total market capitalization recorded $868.31million. The overall volume in the last trading session was 1.89million shares. In its share capital, LXRX has 513.82million outstanding shares.

According to XOMA Corp (NASDAQ:XOMA), it anticipates cash used in ongoing activities during 2014 to be c. $55.0 million to $60.0 million, primarily reflecting the costs associated with conducting the gevokizumab three Phase 3 clinical trials in the EYEGUARD program and the costs associated with conducting a Phase 3 clinical trial in patients with pyoderma gangrenosum. On Thursday, shares of XOMA Corp (NASDAQ:XOMA) dropped -6.11% to close the day at $4.92. Company return on investment (ROI) is -157.30% and its monthly performance is recorded as -27.86%. XOMA Corp (NASDAQ:XOMA) quarterly revenue growth is -28.90%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone